Fenimore Christopher R. 的 Form 4/A 修正申報
修正Regeneron Pharmaceuticals, Inc.（REGN），2021/8/25 申報
- 申報編號
- 0001104659-21-109328
- 申報時間
- 2021/8/25
- 交易日
- 2021/8/20
- 申報延遲
- 5 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
- 原始申報日
- 2021/8/24
這份申報列了 1 筆非衍生性交易。沿用原件裡沒有重述的 9 筆交易。公開市場賣出合計 $313.3 萬。交易後 5 天申報。
這份修正申報重述了 0001237899-21-000017（2021/8/24 申報）的一部分，沒有重述的交易仍然有效，列在下面。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Fenimore Christopher R.CIK 0001697422 | 高階主管（SVP Controller） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2021/8/20 | Common Stock | F扣股繳稅處分 | −8,719 | $664.85 | −$5,796,827.15 | 19,020 | 直接 |
沿用原件的交易
這份修正申報只重述了原件的一部分。原件其他的交易仍然有效，網站的交易表把它們算在這份修正申報底下。
來自 0001237899-21-000017（2021/8/24 申報）。
非衍生性證券（表 I）
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2021/8/20 | Common Stock | M行使選擇權取得 | +13,500 | $179.13 | +$2,418,255 | 32,520 | 直接 | |
| 2021/8/23 | Common Stock | S賣出處分 | −4,576 | $655.00 | −$2,997,280 | 27,944 | 直接 | |
| 2021/8/23 | Common Stock | S賣出處分 | −9 | $659.33F2 | −$5,933.97 | 27,935 | 直接 | |
| 2021/8/23 | Common Stock | S賣出處分 | −23 | $660.33F3 | −$15,187.59 | 27,912 | 直接 | |
| 2021/8/23 | Common Stock | S賣出處分 | −88 | $661.89F4 | −$58,246.32 | 27,824 | 直接 | |
| 2021/8/23 | Common Stock | S賣出處分 | −1 | $662.78 | −$662.78 | 27,823 | 直接 | |
| 2021/8/23 | Common Stock | S賣出處分 | −70 | $663.05F5 | −$46,413.5 | 27,753 | 直接 | |
| 2021/8/23 | Common Stock | S賣出處分 | −14 | $665.21 | −$9,312.94 | 27,739 | 直接 |
衍生性證券（表 II）
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2021/8/20 | Common Stock | M行使選擇權處分 | −13,500 | $0.00 | $0 | 0 | 直接 |
原件的附註
這幾筆交易的價格在原件上引用的附註。
- F2
Represents volume-weighted average price of sales of 9 shares of Company stock on August 23, 2021 at prices ranging from $659.28 to $659.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F3
Represents volume-weighted average price of sales of 23 shares of Company stock on August 23, 2021 at prices ranging from $660.09 to $660.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F4
Represents volume-weighted average price of sales of 88 shares of Company stock on August 23, 2021 at prices ranging from $661.47 to $661.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F5
Represents volume-weighted average price of sales of 70 shares of Company stock on August 23, 2021 at prices ranging from $663.00 to $663.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2
The amount of securities shown following the reported transaction gives effect to the other transactions reported by the Reporting Person in the Original Form 4.
備註
This Form 4/A amends the Form 4 filed by the Reporting Person on August 24, 2021 (the "Original Form 4") by adding a transaction inadvertently omitted from the Original Form 4.